Disproportionate Reduction of Serotonin Transporter May Predict the Response and Adherence to Antidepressants in Patients with Major Depressive Disorder: A Positron Emission Tomography Study with 4-[18F]-ADAM
- Resource Type
- Authors
- Chih-Sung Liang; Chun-Yen Chen; Che Hung Yen; Jia Fwu Shyu; Shin Chang Kuo; Wen Sheng Huang; Kuo-Hsing Ma; Yi Wei Yeh; Fang Jung Wan; Ru Band Lu; San Yuan Huang; Chang Chih Huang; Chyng Yann Shiue; Pei Shen Ho
- Source
- International Journal of Neuropsychopharmacology
- Subject
- Oncology
Adult
Male
medicine.medical_specialty
Benzylamines
positron emission tomography
behavioral disciplines and activities
Article
Reuptake
Young Adult
Thalamus
Mesencephalon
Internal medicine
mental disorders
medicine
Humans
Pharmacology (medical)
antidepressant response
adherence
Psychiatry
Depression (differential diagnoses)
Serotonin transporter
Pharmacology
Serotonin Plasma Membrane Transport Proteins
Depressive Disorder, Major
biology
major depressive disorder
serotonin transporter
Binding potential
Brain
Middle Aged
medicine.disease
Antidepressive Agents
Corpus Striatum
Psychiatry and Mental health
Treatment Outcome
Positron-Emission Tomography
biology.protein
Major depressive disorder
Antidepressant
Female
Serotonin
Radiopharmaceuticals
Psychology
- Language
- English
- ISSN
- 1469-5111
1461-1457
Background: Many lines of evidence suggest the role of serotonin transporter (SERT)-mediated reuptake of serotonin in the pathophysiology and treatment of major depressive disorder (MDD). This study aimed to examine whether the pretreatment of SERT binding potential or SERT binding ratio between terminal projection regions relative to the midbrain raphe nuclei was associated with treatment outcomes to SERT-targeted antidepressants. Methods: We recruited 39 antidepressant-naïve patients with MDD and 39 heathy controls. Positron emission tomography with N,N-dimethyl-2-(2-amino-4-[18F]fluorophenylthio)benzylamine (4-[18F]-ADAM) was used to measure in vivo SERT availability prior to antidepressant treatment. The 21-item Hamilton Depression Rating Scale (HDRS) was use to assess the severity of depression from baseline to week 6. All the patients with MDD had HDRS scores of 18 or more. Results: Pretreatment SERT binding in the thalamus and striatum positively correlated with an early reduction in HDRS scores at week 3. Nonresponders and dropout patients showed a proportionate reduction in SERT binding in the terminal projection regions and midbrain compared to healthy controls. In contrast, a disproportionate reduction in SERT binding in the terminal projection regions relative to midbrain was observed in responders. Conclusions: The results of this study suggested that a disproportionate reduction in SERT binding between terminal projection regions and midbrain may predict better treatment outcomes in patients with MDD.